News

Nurse practitioners give their advice on making treatment choices based on the patient’s medical history and preferences.

The investigational ADC rinatabart sesutecan was given breakthrough therapy designation for use in patients with recurrent/progressive endometrial cancer.

Oncology nurses are needed in research roles, which can provide experience with new therapies, explained Josh Settlemire, MSN, RN, OCN.

CRS is a common but manageable toxicity of CAR T-cell therapy and bispecific antibodies. Learn strategies to identify and manage this adverse effect.

Paolo Tarantino, MD, PhD, discusses ADC structure, toxicity, and nursing consideration for the treatment of patients with breast cancer.

Melissa Rikal, MSN, FNP-BC, AOCNP, shares strategies to help nurses improve adherence and patient education for oral oncolytic therapies.

IMvigor011 showed significant improvement in survival outcomes with adjuvant atezolizumab in ctDNA-positive MIBC.

Nurse practitioner Beth Faiman outlines nursing strategies to monitor, assess, and manage toxicities associated with talquetamab in multiple myeloma.

A significant reduction of opioid use in patients after colorectal surgery was supported by clinician and patient compliance, says Ronald Bleday, MD.

Beyond administering CAR T-cell therapy and bispecifics, oncology nurses must apply proactive, supportive care and an understanding of complex treatments.

A nurse-led clinic to aid in patient-reported symptom burden had high patient satisfaction.

Neurotoxicities can be monitored long term with personalized questions, according to Mary Steinbach, DNP, APRN.

Melissa Rikal, MSN, FNP-BC, AOCNP, explained that adverse effects are common among the available antibody-drug conjugates in breast cancer.

David A. Braun, MD, PhD, explained that personalized cancer vaccines can be associated with toxicities typical of both vaccines and immunotherapies.

In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in patients with T-cell responses.

Oncology nurses play a key role in monitoring, managing, and personalizing CDK4/6 inhibitor treatment to minimize toxicities and protect quality of life, according to Courtney Moore, APRN, FNP-C, OCN.

Findings from a small cohort of a phase 2b trial demonstrated 2-year OS benefit in patients with pulmonary metastatic osteosarcoma treated with OST-HER2.

Treatment access can still affect patients in urban communities, said Mary Steinbach, DNP, APRN.

A breast cancer survivorship expert shares her top advice for counseling patients on endocrine therapy at the 5-year mark.

A care model led by advanced practice nurses was feasible in providing supportive care and linking providers through post-trial care transitions.

Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for AYA patients.

An observational study found IHC may serve as a biomarker for early detection of TP53‐mutant MDS or AML and prediction of TP53 allelic state.

Michelle Kirschner, MSN, RN, ACNP, APRN-BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.

The addition of avutometinib to defactinib showed promising safety and efficacy for patients with low-grade serous ovarian cancer.

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and APPs.

Heather Jackson, PhD, FNP-BC, NEA-BC, FAANP, explains how a fellowship program sets the tone for how to transition nurse practitioners to oncology.

FDA accelerated approval was given to zongertinib for the treatment of patients with unresectable/metastatic nonsquamous NSCLC with HER2 TKD activating mutations.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says Stephanie Mompoint, APRN.